Fubotv earnings beat by $0.10, revenue topped estimates
Lisa Deschamps, a director of Verona Pharma PLC (NASDAQ:VRNA), sold 9,464 ordinary shares of the company on August 1, 2025, at a price of $13.1437, for a total value of $124,391. The transaction comes as VRNA shares trade near their 52-week high of $105.50, having delivered an impressive 402% return over the past year. According to InvestingPro analysis, the stock appears slightly overvalued at its current market capitalization of $9 billion.
On the same day, Deschamps also acquired 24,000 shares through the exercise of restricted stock units at a price of $0. Get deeper insights into VRNA’s valuation metrics and 15+ additional ProTips with InvestingPro.
In other recent news, Merck (NSE:PROR) has announced a significant acquisition, agreeing to purchase Verona Pharma for $107 per American Depository Share in a deal valued at approximately $10 billion. This acquisition is expected to close in the fourth quarter of 2025. The transaction has prompted several analyst actions, with Roth/MKM downgrading Verona Pharma from Buy to Neutral, citing the substantial resources needed to scale Ohtuvayre’s sales. Similarly, BTIG and TD Cowen have downgraded Verona Pharma’s stock rating following the acquisition news. BTIG moved the stock from Buy to Neutral, while TD Cowen adjusted its rating from Buy to Hold, although it raised its price target to $107. Morgan Stanley (NYSE:MS), on the other hand, has reiterated an Equalweight rating on Merck stock with a price target of $99. These developments highlight the strategic moves by Merck and the varied reactions from analysts regarding the acquisition’s impact on Verona Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.